Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma

Abstract Inflammation promotes tumor progression, induces invasion and metastatic spread. This retrospective study explored CRP, CA19-9, and routine laboratory values as preoperative prognostic factors in pancreatic cancer patients. Between 2000 and 2016, there were 212 surgically treated pancreatic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna M. Nurmi, Harri K. Mustonen, Ulf-Håkan Stenman, Hanna E. Seppänen, Caj H. Haglund
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/35f47949fb5443f58bdec73b950f1d0b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:35f47949fb5443f58bdec73b950f1d0b
record_format	dspace
spelling	oai:doaj.org-article:35f47949fb5443f58bdec73b950f1d0b2021-12-02T15:23:00ZCombining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma10.1038/s41598-020-80778-02045-2322https://doaj.org/article/35f47949fb5443f58bdec73b950f1d0b2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80778-0https://doaj.org/toc/2045-2322Abstract Inflammation promotes tumor progression, induces invasion and metastatic spread. This retrospective study explored CRP, CA19-9, and routine laboratory values as preoperative prognostic factors in pancreatic cancer patients. Between 2000 and 2016, there were 212 surgically treated pancreatic cancer patients at Helsinki University Hospital, Finland. Out of these, 76 borderline resectable patients were treated with neoadjuvant therapy (NAT); 136 upfront resected patients were matched for age and sex at a 1:2 ratio. We analyzed preoperative CRP, CA19-9, CEA, leukocytes, albumin, bilirubin and platelets. CRP and CA19-9 were combined into a prognostic score: both CRP and CA19-9 below the cut-off values (3 mg/l and 37 kU/l, respectively), either CRP or CA19-9 above the cut-off value, and finally, both CRP and CA19-9 above the cut-off values. Among all patients, median disease-specific survival times were 54, 27 and 16 months, respectively (p < 0.001). At 5 years, among patients with CRP and CA19-9 levels below the cut-off values, 49% were alive and 45% were disease-free. Among NAT patients the corresponding survival rates were 52% and 45% and among those undergoing upfront surgery 45% and 40%, respectively. This novel prognostic score combining CRP and CA19-9 serves as a useful preoperative tool estimating survival.Anna M. NurmiHarri K. MustonenUlf-Håkan StenmanHanna E. SeppänenCaj H. HaglundNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Anna M. Nurmi Harri K. Mustonen Ulf-Håkan Stenman Hanna E. Seppänen Caj H. Haglund Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
description	Abstract Inflammation promotes tumor progression, induces invasion and metastatic spread. This retrospective study explored CRP, CA19-9, and routine laboratory values as preoperative prognostic factors in pancreatic cancer patients. Between 2000 and 2016, there were 212 surgically treated pancreatic cancer patients at Helsinki University Hospital, Finland. Out of these, 76 borderline resectable patients were treated with neoadjuvant therapy (NAT); 136 upfront resected patients were matched for age and sex at a 1:2 ratio. We analyzed preoperative CRP, CA19-9, CEA, leukocytes, albumin, bilirubin and platelets. CRP and CA19-9 were combined into a prognostic score: both CRP and CA19-9 below the cut-off values (3 mg/l and 37 kU/l, respectively), either CRP or CA19-9 above the cut-off value, and finally, both CRP and CA19-9 above the cut-off values. Among all patients, median disease-specific survival times were 54, 27 and 16 months, respectively (p < 0.001). At 5 years, among patients with CRP and CA19-9 levels below the cut-off values, 49% were alive and 45% were disease-free. Among NAT patients the corresponding survival rates were 52% and 45% and among those undergoing upfront surgery 45% and 40%, respectively. This novel prognostic score combining CRP and CA19-9 serves as a useful preoperative tool estimating survival.
format	article
author	Anna M. Nurmi Harri K. Mustonen Ulf-Håkan Stenman Hanna E. Seppänen Caj H. Haglund
author_facet	Anna M. Nurmi Harri K. Mustonen Ulf-Håkan Stenman Hanna E. Seppänen Caj H. Haglund
author_sort	Anna M. Nurmi
title	Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
title_short	Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
title_full	Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
title_fullStr	Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
title_full_unstemmed	Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
title_sort	combining crp and ca19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/35f47949fb5443f58bdec73b950f1d0b
work_keys_str_mv	AT annamnurmi combiningcrpandca199inanovelprognosticscoreinpancreaticductaladenocarcinoma AT harrikmustonen combiningcrpandca199inanovelprognosticscoreinpancreaticductaladenocarcinoma AT ulfhakanstenman combiningcrpandca199inanovelprognosticscoreinpancreaticductaladenocarcinoma AT hannaeseppanen combiningcrpandca199inanovelprognosticscoreinpancreaticductaladenocarcinoma AT cajhhaglund combiningcrpandca199inanovelprognosticscoreinpancreaticductaladenocarcinoma
_version_	1718387316731412480

Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma

Ejemplares similares